449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy

التفاصيل البيبلوغرافية
العنوان:	449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy
المؤلفون:	Julie Rytlewski, Leanne Peiser, Jerill Thorpe, Heidi Gillenwater, Ken Ogasawara, Yeonhee Kim, Diana Shpektor, Eniko Papp
المصدر:	Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
بيانات النشر:	BMJ Publishing Group, 2021.
سنة النشر:	2021
المجموعة:	LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
نوع الوثيقة:	article
وصف الملف:	electronic resource
اللغة:	English
تدمد:	2051-1426
Relation:	https://doaj.org/toc/2051-1426
DOI:	10.1136/jitc-2021-SITC2021.449
URL الوصول:	https://doaj.org/article/1603585596764915b3aaf112d600f635
رقم الأكسشن:	edsdoj.1603585596764915b3aaf112d600f635
قاعدة البيانات:	Directory of Open Access Journals

الوصف
تدمد:	20511426
DOI:	10.1136/jitc-2021-SITC2021.449